Literature DB >> 23524461

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes.

Kevan C Herold1, Dario A A Vignali, Anne Cooke, Jeffrey A Bluestone.   

Abstract

Type 1 diabetes (T1D) remains an important health problem, particularly in western countries, where the incidence has been increasing in younger children. In 1986, Eisenbarth described T1D as a chronic autoimmune disease. Work over the past three-and-a-half decades has identified many of the genetic, immunological and environmental factors that are involved in the disease and have led to hypotheses concerning its pathogenesis. Clinical trials have been conducted to test these hypotheses but have had mixed results. Here, we discuss the findings that have led to our current concepts of the disease mechanisms involved in T1D and the clinical studies promoted by these studies. The findings from preclinical and clinical studies support the original proposed model for how T1D develops but have also suggested that this disease is more complex than was originally thought and will require broader treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23524461      PMCID: PMC4172461          DOI: 10.1038/nri3422

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  174 in total

Review 1.  The hygiene hypothesis: an explanation for the increased frequency of insulin-dependent diabetes.

Authors:  Jean-François Bach; Lucienne Chatenoud
Journal:  Cold Spring Harb Perspect Med       Date:  2012-02       Impact factor: 6.915

2.  GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.

Authors:  Johnny Ludvigsson; David Krisky; Rosaura Casas; Tadej Battelino; Luis Castaño; James Greening; Olga Kordonouri; Timo Otonkoski; Paolo Pozzilli; Jean-Jacques Robert; Henk J Veeze; Jerry Palmer; Ulf Samuelsson; Helena Elding Larsson; Jan Åman; Gunilla Kärdell; Jan Neiderud Helsingborg; Göran Lundström; Eva Albinsson; Annelie Carlsson; Maria Nordvall; Hans Fors; Carl-Göran Arvidsson; Stig Edvardson; Ragnar Hanås; Karin Larsson; Björn Rathsman; Henrik Forsgren; Helena Desaix; Gun Forsander; Nils-Östen Nilsson; Carl-Göran Åkesson; Päivi Keskinen; Riitta Veijola; Timo Talvitie; Klemens Raile; Thomas Kapellen; Walter Burger; Andreas Neu; Ilse Engelsberger; Bettina Heidtmann; Suzanne Bechtold; David Leslie; Francesco Chiarelli; Alesandro Cicognani; Giuseppe Chiumello; Franco Cerutti; Gian Vincenzo Zuccotti; Ana Gomez Gila; Itxaso Rica; Raquel Barrio; Maria Clemente; Maria José López Garcia; Mercedes Rodriguez; Isabel Gonzalez; Juan Pedro Lopez; Mirentxu Oyarzabal; H M Reeser; Roos Nuboer; Pauline Stouthart; Natasa Bratina; Nina Bratanic; Marc de Kerdanet; Jacques Weill; Nicole Ser; Pascal Barat; Anne Marie Bertrand; Jean-Claude Carel; Rachel Reynaud; Regis Coutant; Sabine Baron
Journal:  N Engl J Med       Date:  2012-02-02       Impact factor: 91.245

3.  Inhibition of nicotinamide phosphoribosyltransferase modifies LPS-induced inflammatory responses of human monocytes.

Authors:  Erik Schilling; Janine Wehrhahn; Carina Klein; Nora Raulien; Uta Ceglarek; Sunna Hauschildt
Journal:  Innate Immun       Date:  2011-10-05       Impact factor: 2.680

4.  Diabetes incidence is unaltered in glutamate decarboxylase 65-specific TCR retrogenic nonobese diabetic mice: generation by retroviral-mediated stem cell gene transfer.

Authors:  Paula Y Arnold; Amanda R Burton; Dario A A Vignali
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

5.  Investigation of the role of B-cells in type 1 diabetes in the NOD mouse.

Authors:  F Susan Wong; Li Wen; Michelle Tang; Murugappan Ramanathan; Irene Visintin; Joanne Daugherty; Lynn G Hannum; Charles A Janeway; Mark J Shlomchik
Journal:  Diabetes       Date:  2004-10       Impact factor: 9.461

6.  Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes.

Authors:  Elmar Jaeckel; Myra A Lipes; Harald von Boehmer
Journal:  Nat Immunol       Date:  2004-09-19       Impact factor: 25.606

7.  Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients.

Authors:  Ken T Coppieters; Francesco Dotta; Natalie Amirian; Peter D Campbell; Thomas W H Kay; Mark A Atkinson; Bart O Roep; Matthias G von Herrath
Journal:  J Exp Med       Date:  2012-01-02       Impact factor: 14.307

8.  NK cells are not required for spontaneous autoimmune diabetes in NOD mice.

Authors:  Joshua N Beilke; Craig T Meagher; Karoline Hosiawa; Marine Champsaur; Jeffrey A Bluestone; Lewis L Lanier
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

9.  Germline TRAV5D-4 T-cell receptor sequence targets a primary insulin peptide of NOD mice.

Authors:  Maki Nakayama; Todd Castoe; Tomasz Sosinowski; XiangLing He; Kelly Johnson; Kathryn Haskins; Dario A A Vignali; Laurent Gapin; David Pollock; George S Eisenbarth
Journal:  Diabetes       Date:  2012-02-07       Impact factor: 9.461

10.  Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients.

Authors:  Frank Waldron-Lynch; Octavian Henegariu; Songyan Deng; Paula Preston-Hurlburt; James Tooley; Richard Flavell; Kevan C Herold
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

View more
  104 in total

Review 1.  Endocrinology research-reflecting on the past decade and looking to the next.

Authors:  Kevan C Herold; Joseph A Majzoub; Shlomo Melmed; Merri Pendergrass; Martin Schlumberger
Journal:  Nat Rev Endocrinol       Date:  2015-10-13       Impact factor: 43.330

2.  Depletion of IL-2 receptor β-positive cells protects from diabetes in non-obese diabetic mice.

Authors:  Hanna Brauner; Håkan T Hall; Malin Flodström-Tullberg; Klas Kärre; Petter Höglund; Sofia Johansson
Journal:  Immunol Cell Biol       Date:  2015-08-05       Impact factor: 5.126

3.  CCR7 directs the recruitment of T cells into inflamed pancreatic islets of nonobese diabetic (NOD) mice.

Authors:  Zhongyan Shan; Baohui Xu; Anna Mikulowska-Mennis; Sara A Michie
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

4.  Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Jeongheon Yoon; William E Culp; Jason R Lees; Kai W Wucherpfennig; David W Scott
Journal:  J Autoimmun       Date:  2018-05-30       Impact factor: 7.094

5.  α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.

Authors:  Peter A Gottlieb; Aimon K Alkanani; Aaron W Michels; Eli C Lewis; Leland Shapiro; Charles A Dinarello; Danny Zipris
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

Review 6.  Biomarkers in type 1 diabetes: application to the clinical trial setting.

Authors:  James E Tooley; Kevan C Herold
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-08       Impact factor: 3.243

7.  Retro-inverso D-peptides as a novel targeted immunotherapy for Type 1 diabetes.

Authors:  Angela Lombardi; Erlinda Concepcion; Hanxi Hou; Hanane Arib; Mihaly Mezei; Roman Osman; Yaron Tomer
Journal:  J Autoimmun       Date:  2020-09-17       Impact factor: 7.094

Review 8.  Toll-like receptor-mediated immune responses in intestinal macrophages; implications for mucosal immunity and autoimmune diseases.

Authors:  Zejun Zhou; Miao Ding; Lei Huang; Gary Gilkeson; Ren Lang; Wei Jiang
Journal:  Clin Immunol       Date:  2016-09-09       Impact factor: 3.969

Review 9.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 10.  Immunometabolism and autoimmunity.

Authors:  Jenny Freitag; Luciana Berod; Thomas Kamradt; Tim Sparwasser
Journal:  Immunol Cell Biol       Date:  2016-08-26       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.